Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.67 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.61 |
| ▸ | PRSS2 | P07478 | 6/20 | 0.61 |
| ▸ | PRSS3 | P35030 | 6/20 | 0.61 |
| ▸ | TPSAB1 | Q15661 | 8/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6804030 | 0.95 | F10 (0.76) | F10PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL972001 | 0.95 | F10 (0.62) | F10PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL4408248 | 0.87 | F10 (0.71) | F10PRSS1PRSS2PRSS3TPSAB1 | |
| Trifluoroacetic Acid SCHEMBL1381804 | 0.84 | F10 (0.80) | F10PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL15788530 | 0.84 | F10 (0.51) | F10PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL6807311 | 0.84 | F10 (0.49) | F10PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL6808390 | 0.84 | F10 (0.55) | F10PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL18652788 | 0.83 | F10 (0.49) | F10PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL302010 | 0.83 | F10 (0.51) | F10PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL15788529 | 0.83 | F10 (0.50) | F10PRSS1PRSS2PRSS3TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4851440-B2 | — | — | 2012-01-11 | — | — | JP | claimed |
| EP-1723140-B1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-11-04 | — | — | EP | claimed |
| US-20070197597-A1 | Process for the preparation of tryptase inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | claimed |
| EP-1723140-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-11-22 | — | — | EP | claimed |
| WO-2005095385-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | WO | claimed |
| EP-1571150-A1 | Process for the preparation of tryptase inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2005-09-07 | — | — | EP | claimed |
| EP-4665322-A1 | DYSREGULATION OF PLANKTONIC BACTERIAL METABOLISM | Neolixir Limited (AU) | 2025-12-24 | — | — | EP | disclosed |
| US-20240397944-A1 | METHODS FOR BIOFILM DISRUPTION | Lixa Limited (AU) | 2024-12-05 | — | — | US | disclosed |
| WO-2024229525-A1 | DYSREGULATION OF PLANKTONIC BACTERIAL METABOLISM | Neolixir Limited (AU) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429651-A1 | METHODS FOR BIOFILM DISRUPTION | Neolixir Limited (AU) | 2024-09-18 | — | — | EP | disclosed |
| CN-118251216-A | Method for biofilm disruption | 尼尔利希尔有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-112279772-B | Alpha, alpha-dideuteronamine compound, deuterated medicament and preparation method thereof | 北京奇点势能科技有限公司 | 2023-06-30 | — | — | CN | disclosed |
| WO-2023081974-A1 | METHODS FOR BIOFILM DISRUPTION | Neolixir Pty Ltd (AU) | 2023-05-19 | — | — | WO | disclosed |
| US-20070197597-A1 | Process for the preparation of tryptase inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| EP-1723140-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005095385-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005095385-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| EP-1571150-A1 | Process for the preparation of tryptase inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004060884-A1 | [4-(3-AMINOMETHYLPHENYL) PIPERIDIN-1-YL]- [5-(2-FLUOROPHENYLETHYNYL)FURAN-2-YL]-METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060884-A1 | [4-(3-AMINOMETHYLPHENYL) PIPERIDIN-1-YL]- [5-(2-FLUOROPHENYLETHYNYL)FURAN-2-YL]-METHANONE AS AN INHIBITOR OF MAST CELL TRYPTASE | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240397944-A1 | METHODS FOR BIOFILM DISRUPTION | FGB, MMP8, HAO2 | F10 471/4885PRSS1 1004/4885PRSS2 503/4885 |
| US-20070197597-A1 | Process for the preparation of tryptase inhibitors | CMA1, TPSAB1, TPSB2 | F10 224/4885PRSS1 20/4885PRSS2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.